ID1201 / Ildong - LARVOL DELTA

Will the domestic pharmaceutical company develop ’new dementia’ speed up?…[Google translation] (Consumer News) - "'ID1201'...which Ildong Pharmaceutical is developing as a new drug for dementia, is also about to start phase 3 ID1201...for dementia...In August of last year, it was approved for a large-scale phase 3 clinical trial in 1449 patients with mild Alzheimer's disease. An official from Ildong Pharmaceutical said, 'Phase 3 has not been discontinued and is in preparation. We are undergoing preparation procedures for clinical trials such as selection of medical institutions and recruitment of subjects.' It explains that the possibility of clinical initiation is open."

New P3 trial • Alzheimer's Disease • CNS Disorders

Global pharmaceutical companies fail to cure dementia … What is Ildong Pharmaceutical? (docdocdoc.co.kr) - "ID1201, a drug for Alzheimer's disease, is being approved by the Food and Drug Administration for its Phase III clinical trials, and it is being watched by domestic pharmaceutical companies that they will succeed in developing dementia treatments that have been abandoned by global pharmaceutical companies...Ildong Pharma has been approved for phase III clinical trials in the first four months of phase 2 clinical trials of ID1201, and is looking forward to the success of the treatment."

New P3 trial

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease (clinicaltrials.gov) - P2; N=116; Completed; Sponsor: IlDong Pharmaceutical Co Ltd; Active, not recruiting ➔ Completed; Trial completion date: Dec 2018 ➔ Apr 2019

Clinical • Trial completion • Trial completion date